New Technology– category –
-
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Receives FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathy
StreetInsider USA Overview IPS HEART, Inc. announced that its iPSC-derived cell replacement therapy, ISX9-CPC, has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for cardiomyopathy associated with muscular dystrophi... -
AI and 3D Bioprinting Transform Regenerative Medicine: Companies like BioLattice Accelerate Organ Manufacturing with Real-Time Quality Control and Optimized Bioinks
Ahead of the Herd Unknown Overview The convergence of artificial intelligence (AI) and 3D bioprinting is accelerating the manufacturing of organs and tissues in regenerative medicine. AI significantly enhances 3D bioprinting accuracy and... -
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients... -
Real-World Data Reveals 83.9% Treatment Failure Rate in Second-Line Diffuse Large B-Cell Lymphoma Despite New Therapies; CAR-T Patients Show 26.4-Month Median OS
MDNewsline Unknown Overview Despite the introduction of novel therapies, real-world treatment patterns for Diffuse Large B-Cell Lymphoma (DLBCL) continue to face challenges with poor patient prognosis and high treatment failure rates in ... -
IMBIOORG2026 Conference Highlights Latest Trends and Partnerships in 3D Bioprinting and Organ Regeneration
InSciTech Summits International Overview The IMBIOORG2026 international conference will showcase cutting-edge research, innovations, and transformative applications in 3D bioprinting, tissue engineering, regenerative medicine, and organ ... -
U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designations: 168 Publicly Announced by 2026, Accelerating Transformative Therapies in Oncology and Rare Diseases
BioInformant USA Overview According to BioInformant, as of August 2026, the U.S. FDA has publicly announced 168 Regenerative Medicine Advanced Therapy (RMAT) designations. These designations are granted to cell and gene therapy products ... -
Advances in 3D Bioprinting for Organoid Construction: Enhancing Physiological Relevance and Promoting Diverse Biomedical Applications
PMC (NIH) International Overview A comprehensive review article highlights recent advancements in 3D bioprinting technology for organoid construction. This technique overcomes challenges of traditional organoid culture methods by precise... -
Washington University-Developed CAR-T Therapy for T-Cell Leukemia and Lymphoma Receives FDA Breakthrough Therapy Designation: Off-the-Shelf Approach Improves Access
Washington University School of Medicine in St. Louis USA Overview A cell-based immunotherapy developed by Washington University School of Medicine in St. Louis, designed to treat rare and aggressive T-cell acute lymphoblastic leukemia a... -
FDA Grants Four Regenerative Medicine Advanced Therapy (RMAT) Designations in July: Advancements in Musculoskeletal, Ophthalmic, Oncology, and Neurological Fields
Pharmacally USA Overview In July 2026, the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to four distinct investigational drugs, spanning diverse regenerative medicine modalities including cell therapies, ge... -
Promises and Pitfalls of In Vivo CAR Gene Therapy: Clinical Proof-of-Concept Progresses Amidst Focus on Safety and Biological Factors
Blood - ASH Publications USA Overview While ex vivo CAR-T cell therapies demonstrate high efficacy in lymphoid hematologic malignancies, their logistical complexity and high costs limit patient access. In contrast, in vivo CAR gene thera...
